Results 51 to 60 of about 1,213 (150)

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates   +7 more
wiley   +1 more source

Ketoacidosis without significantly hyperglycaemia - is it possible?

Journal of Education, Health and Sport, 2017
Introduction and aim of the study. Currently only minimal information is available regarding ketoacidosis without significant hyperglycemia. Some study describe that the sodium –glucose cotransporters (SGLT) may alter the normal balance between ...
Michał Budzyński, Joanna Pekar, Justyna Magdalena Skolarczyk, Monika Tadla, Katarzyna Skórzyńska-Dziduszko   +4 more
doaj   +3 more sources

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 170-188, June 2026.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Influence of long term administration of tofogliflozin on chronic inflammation of visceral adipose tissue in mice with obesity induced by a high-fat diet.

PLoS ONE, 2019
We previously found that senescence of cluster of differentiation 4 (CD4) T cells is accelerated in the visceral adipose tissue (VAT) of mice with diet-induced obesity (DIO) due to a high-fat diet (HFD), and that these senescent-associated T cells cause ...
Kohsuke Shirakawa, Wataru Yano, Keisuke Inoue, Yoshinori Katsumata, Jin Endo, Motoaki Sano   +5 more
doaj   +1 more source

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis

Cells, 2022
Ballooning degeneration of hepatocytes is a major distinguishing histological feature of non-alcoholic steatosis (NASH) progression that can lead to cirrhosis and hepatocellular carcinoma (HCC).
Kentaro Murakami, Yusuke Sasaki, Masato Asahiyama, Wataru Yano, Toshiaki Takizawa, Wakana Kamiya, Yoshihiro Matsumura, Motonobu Anai, Tsuyoshi Osawa, Jean-Charles Fruchart, Jamila Fruchart-Najib, Hiroyuki Aburatani, Juro Sakai, Tatsuhiko Kodama, Toshiya Tanaka   +14 more
doaj   +1 more source

Interrelationship Between Baseline HbA1c, SGLT‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.
ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu, Setor K. Kunutsor, Erwin Taguiam, Kamlesh Khunti   +3 more
wiley   +1 more source

NetMetaEasy: enabling rapid and user‐friendly network meta‐analysis (NMA) for comparative effectiveness research

British Journal of Pharmacology, Volume 183, Issue 9, Page 1814-1823, May 2026.
Background and Purpose Network meta‐analysis (NMA) enables the simultaneous comparison of multiple treatments by combining direct and indirect evidence across a network of studies. While its application is rapidly expanding in pharmacological research and clinical guideline development, performing NMA typically requires advanced statistical knowledge ...
János Tibor Fekete, András Komócsi, Balázs Győrffy   +2 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses

Endocrinology, Diabetes & Metabolism
Aims How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes has not been clinically demonstrated. Thus, we compared time courses of gamma‐glutamyltransferase (GGT) and alanine aminotransferase (ALT) with ...
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura, Hideki Suganami   +5 more
doaj   +1 more source

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

Molecules, 2020
Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the ...
Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Hideaki Yokoo, Aya Osaki, Yoko Shimoda, Atsushi Ozawa, Yasuyo Nakajima, Jeffrey E. Pessin, Shuichi Okada, Masanobu Yamada   +10 more
doaj   +1 more source